Efficacy and safety of antifibrotic agents for interstitial lung disease associated with rheumatoid arthritis
Not Applicable
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-UMIN000052195
- Lead Sponsor
- Yokohama City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are in conflict with any of the following will not be included in this study: 1. patients complicated with collagen diseases other than RA 2. patients with a hospital history of less than 6 months
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To collect clinical information from patients registered in the Yokohama City University Rheumatic disease Database (Y-CURD) and patients with RA-ILD attending the Kanagawa Cardiovascular and Respiratory Disease Center. 1. Lung cancer complication rate 2. ILD relapse rate 3. Overall survival We evaluate these outcomes with/without antifibrotic agents.
- Secondary Outcome Measures
Name Time Method